Spectral AI Provides 2023-2024 Annual Revenue Guidance
2023年10月23日 - 9:00PM
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today provided annual revenue
guidance for the fiscal years ending December 31, 2023 and 2024 and
highlighted plans and opportunities associated with the ongoing
development and commercialization of its AI-Driven DeepView® Wound
Imaging Technology for diabetic foot ulcers (“DFU”), burn and other
indications.
The Company recently announced the largest
contract in its history, an award from the U.S. Government valued
at over $149.0 million, which brings the total U.S. Government
awards to the Company since 2019 to over $246.0 million. With this
contract in hand, the Company now has far greater visibility into
its research and development revenues for 2023 and 2024 and is
pleased to provide this information to the Company’s
shareholders.
Financial Guidance
- Research & Development Revenue (“Revenue”) for FY2023 is
expected to approximate $17.4 million
- Revenue for FY2024 is expected to
approximate $28.0 million
“We are on the cusp of delivering a distinct,
cutting-edge AI-driven wound healing assessment platform with the
potential to significantly improve the current standard of care
across multiple indications,” said Wensheng Fan, CEO of Spectral
AI. “As we continue to advance our burn indication, we are as
excited about the prospects for the use of DeepView® for DFU, an
estimated $11.0 billion market that we believe is in dire need of a
solution that provides clinicians with an immediate healing
assessment for more accurate and timely diagnosis and therapeutic
intervention. We intend to submit applications for FDA, UKCA, and
CE mark approval for the DeepView® DFU indication, as well as for
3D wound measurement capabilities, in FY2024 subject to the
completion of ongoing studies.”
The Company noted that the financial guidance
for FY2024 does not reflect the material financial contributions it
expects would result from the commercialization of DeepView® for
DFU and 3D wound measurement following the receipt of necessary
regulatory clearances. As previously disclosed, the Company has
received regulatory approval for the DeepView SnapShot® device
and the Company will now seek the approval of its integrated AI
application to obtain both UKCA and FDA approval for the
commercialization of the complete DeepView SnapShot® System in
the United States and across the globe.
“We believe we are in the best position in our
history to deliver significant value for patients dealing with
acute and chronic wound conditions, physicians and health systems
that are challenged with effectively and cost-efficiently managing
these conditions, and, of course, our shareholders,” Mr. Fan
concluded.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive
AI company focused on medical diagnostics for faster and more
accurate treatment decisions in wound care, with initial
applications involving patients with burns and diabetic foot
ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView® System.
DeepView® is a predictive diagnostic device that offers clinicians
an objective and immediate assessment of a wound’s healing
potential prior to treatment or other medical intervention. With
algorithm-driven results and a goal of substantially exceeding the
current standard of care in the future, DeepView® is expected to
provide faster and more accurate treatment insight towards value
care by improving patient outcomes and reducing healthcare costs.
For more information about DeepView®, visit
www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are
“forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions, or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Contacts:Investors:Spectral
AIChristine MarksVP Marketing and
Commercializationir@spectral-ai.com
The Equity GroupDevin Sullivan, Managing
Directordsullivan@equityny.comConor Rodriguez,
Analystcrodriguez@equityny.com
Media:Russo PartnersDavid
SchullRusso Partners(858)
717-2310david.schull@russopartnersllc.com
Guillermo Ruiz, M.D., Ph.D.Russo Partners(646)
218-4604guillermo.ruiz@russopartnersllc.com
Spectral AI (NASDAQ:MDAI)
過去 株価チャート
から 5 2024 まで 6 2024
Spectral AI (NASDAQ:MDAI)
過去 株価チャート
から 6 2023 まで 6 2024